Claire Elizabeth Brandish

Mrs. Claire Elizabeth Brandish


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2024 in Biomed
Verified
Journal Article
Open access
PDF file
AIAyesha Iqbal
Ayesha Iqbal
Yuhashinee KumaradevYuhashinee Kumaradev
Yuhashinee Kumaradev
GGGizem Gülpınar
Gizem Gülpınar
Claire Elizabeth BrandishClaire Elizabeth Brandish
Claire Elizabeth Brandish
Maxencia NabiryoMaxencia Nabiryo
Maxencia Nabiryo
VRVictoria Rutter
Victoria Rutter
Background: The hub-and-spoke model (HSM) offers a framework for efficient healthcare service delivery. This scoping review seeks to explore the implementation and effectiveness of the HSM in antimicrobial stewardship (AMS) programmes. Methods: The Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR) reporting guideline was followed. A systematic search was conducted in four electronic databases (PubMed, Medline, Cochrane Library, and Google Scholar) from inception until January 2024. Studies where the HSM was used for delivering any AMS activity, intervention, or action, were included. No study-specific filters were applied and all populations, study designs, and health settings were included. Data screening and selection were achieved using Rayyan. Three authors independently screened studies, with conflicts resolved by a fourth author. Data were narratively synthesised. Standard appraisal tools were impractical; however, critical evaluation of data collection and outcome reporting was ensured. Results: Out of 1438 articles, three were included in the scoping review. The primary interventions utilising the HSM in AMS involved reducing antibiotic misuse, training healthcare professionals, case-based learning, establishing AMS programmes, developing antibiograms, and formulating policies or guidelines pertinent to AMS. The studies demonstrated significant clinical improvements in AMS. Clinical outcomes from the studies include a significant reduction in antimicrobial usage and improved antibiotic management, with a notable decrease in days on antimicrobial therapy and increased antibiotic de-escalation. Key facilitators for AMS programme success were tailored education, collaborative learning, strong leadership, strategic practices, and data-driven decisions. Key barriers were leadership challenges, change resistance, knowledge gaps, inadequate data systems, resource limitations, and technological constraints. Conclusions: The review identified a literature gap in HSM use in AMS programmes. Further studies are needed to assess HSM’s effectiveness, feasibility, and cost-effectiveness in AMS contexts.

6 October 2025 in Journal of Pharmaceutical Policy and Practice
Verified
Journal Article
Open access
David MusokeDavid Musoke
David Musoke
GLGrace Biyinzika Lubega
Grace Biyinzika Lubega
CNCarol Esther Nabbanja
Carol Esther Nabbanja
FNFilimin Niyongabo
Filimin Niyongabo
MBMichael Obeng Brown
Michael Obeng Brown
LGLinda Gibson
Linda Gibson
Substandard and falsified medicines (SFMs) continue to pose a significant threat to public health globally. However, there is limited evidence on use of SFMs for both humans and animals particularly in low- and middle-income countries such as Uganda. The study assessed knowledge, attitudes and practices on SFMs for human and animal use in Wakiso District, Uganda. A cross-sectional survey that employed a structured questionnaire among 432 community members was conducted in Wakiso District. The questionnaire assessed knowledge, attitudes and practices on SFMs for human and animal use. Data was collected using the KoboCollect mobile application hosted on tablet computers. Univariate data analysis was conducted in Stata Version 14. The majority of respondents (83%) stated that they had heard about SFMs although only 31% could correctly define them. Only 7% of the respondents accurately identified a falsified medicine despite 24% stating that they believed they could recognise SFMs. Almost two-thirds (62% and 60%) of the respondents disagreed that most human and animal SFMs respectively were as good as genuine medicines. Most of the respondents strongly agreed or agreed that SFMs could be very dangerous for humans (96%) and for animals (95%). Respondents reported having bought products they suspected were SFMs for use in humans (14%) and animals (24%). Seeking health worker advice on the medicine brand (40%) / getting medicine from a trustworthy pharmacy (34%) for humans; and seeking a veterinary officer’s advice for choosing the brand (43%) / getting medicine from a trustworthy veterinary pharmacist (29%) for animals were the most common measures respondents reported taking to ensure the medicine bought was genuine. Only 25% of the respondents mentioned informing a health worker and only 4% had reported suspicions of SFMs to the National Drug Authority. Despite commendable attitudes, there was generally limited knowledge and related poor practices regarding SFMs for both humans and animals. There is a need for key stakeholder engagement involving health and regulatory authorities in both human and animal medicine to increase awareness on SFMs to minimise the potential risks to health among the community.

2 February 2026 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Closed access
PDF file
SHStephen Hughes
Stephen Hughes
JCJamie Cheong
Jamie Cheong
JSJonathan Snape
Jonathan Snape
SJShilpa Jethwa
Shilpa Jethwa
SNSong Heng Ng
Song Heng Ng
RHRyan Hamilton
Ryan Hamilton
Teicoplanin exhibits complex pharmacokinetics with substantial inter-patient variability. Therapeutic drug monitoring (TDM) is recommended to ensure adequate exposure, yet contemporary data on real-world prescribing practices are scarce. We evaluated current teicoplanin dosing and monitoring practices across UK and Irish hospitals. We conducted a multicentre, retrospective cohort study (Teicoplanin in UK: Study of Hospital Practice; TUcK–SHOP) across 21 hospitals. Adults receiving ≥5 days of intravenous/intramuscular teicoplanin with at least one TDM sample were included. Primary outcome was adherence to local or national dosing guidelines. Secondary outcomes included initial trough level attainment (≥20 mg/L) and laboratory-confirmed toxicity. Multivariable linear regression identified predictors of first trough concentrations. A total of 391 patients met inclusion criteria (median age 69 years; 57.5% male). Guideline adherence was 66% overall but varied widely between sites (5%–100%). Most patients received three-dose loading (61.3%) with median maintenance dosing of 10.6 mg/kg daily (IQR 7.3–12.1). Median first trough level was 24.6 mg/L (IQR 17.9–33.2); only 40.8% of patients on 6 mg/kg maintenance achieved ≥20 mg/L versus 86.6% on 12 mg/kg (P < 0.001). Independent predictors of higher trough levels included lower creatinine clearance, longer time to TDM sampling, higher loading and maintenance doses, and greater body weight (adjusted R2 = 0.26, P < 0.001). Dose adjustments were required in 30% of patients. Teicoplanin prescribing demonstrates significant variation across UK and Irish hospitals. Higher maintenance dosing (10–12 mg/kg) predicts therapeutic target attainment. These real-world data support the need for standardized dosing protocols to optimize teicoplanin therapy.

3 December 2025 in Antibiotics
Verified
Journal Article
Open access
PDF file
AIAyesha Iqbal
Ayesha Iqbal
GGGizem Gülpınar
Gizem Gülpınar
Claire Elizabeth BrandishClaire Elizabeth Brandish
Claire Elizabeth Brandish
Maxencia NabiryoMaxencia Nabiryo
Maxencia Nabiryo
FGFrances Garraghan
Frances Garraghan
VRVictoria Rutter
Victoria Rutter
Introduction: The hub-and-spoke model (HSM) offers a methodological and hierarchical project management framework for efficient healthcare service delivery. The Commonwealth Partnerships for Antimicrobial Stewardship (CwPAMS) programme supports the development and implementation of antimicrobial stewardship (AMS) interventions to optimise the use of antimicrobials across eight African countries: Ghana, Kenya, Malawi, Nigeria, Sierra Leone, Tanzania, Uganda, and Zambia. Currently the second phase of the programme (CwPAMS 2.0) is being implemented, between March 2023 and March 2025, in which six countries are adopting the HSM to deliver AMS interventions. The aim of this study was to design a hybrid II monitoring, evaluation and learning (MEL) framework to assess the implementation and effectiveness of the HSM in delivering and adapting AMS interventions. Methods: A mixed-methods Hybrid II Implementation trial design was used to develop the MEL framework, guided by the Theory of Change, Socio-Ecological Theory, and Normalisation Process Theory and in alignment with the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) framework. Data collection will be continuous and longitudinal (pre-, mid- and post-implementation). The evaluation framework has been designed to study implementation evaluation at three ecological levels: programme, partnership, and individual site level. Data collection will encompass mixed methodologies and include non-participant observations, formal and informal feedback (from individual key stakeholders and groups), knowledge tools and surveys, scored evaluations, pre-and post-assessments, semi-structured interviews, focus groups, and data collected during formal and informal meetings. This approach will facilitate continuous data collection for evaluation and help study the utilisation and adaptation of AMS interventions. Discussion: This study provides a protocol for developing and utilising an MEL framework to study the application of the HSM in delivering AMS interventions. Developing an evaluation framework requires meticulous planning and a robust implementation and evaluation protocol to ensure methodological rigour, transparency, and effective resource management throughout the project lifecycle. Despite comprehensive consideration of developing progress and programmatic indicators and measures across all domains, the study acknowledges limitations in definitively attributing causality to individual AMS interventions due to their complexity and varied implementation contexts.

27 August 2026 in Antibiotics
Verified
Journal Article
Open access
PDF file
SPSiân Price
Siân Price
YTYen Truong
Yen Truong
PZParia Sanaty Zadeh
Paria Sanaty Zadeh
GTGloria Tumukunde
Gloria Tumukunde
Claire Elizabeth BrandishClaire Elizabeth Brandish
Claire Elizabeth Brandish
CSChiko Savieli
Chiko Savieli
Background: Antimicrobial resistance is a growing global health challenge, particularly in low- and middle-income countries where antimicrobial stewardship (AMS) implementation and leadership capacity remain limited. Pharmacists play a central role in AMS but often lack access to structured leadership development. To address this gap, the Commonwealth Pharmacists Association developed the UK–Africa Leadership Fellowship in Antimicrobial Stewardship (UK-ALF-A), a 12-month bidirectional leadership development programme combining online learning modules, live webinars, peer-learning sessions, dual mentorship from UK- and Africa-based mentors, and workplace-based AMS continuous quality improvement projects. UK-ALF-A was designed to strengthen leadership capability among pharmacists in the United Kingdom and sub-Saharan Africa. Methods: This study evaluated changes in leadership capability among pharmacists participating in the programme and explored how fellows applied these capabilities within AMS-related practice. A mixed-methods evaluation was conducted with 40 fellows (20 UK, 20 Africa), using pre- and post-programme self-assessments and 360-degree colleague feedback based on the International Pharmaceutical Federation Global Advanced Development Framework (FIP GADF), alongside post-fellowship surveys and semi-structured interviews. Results: The proportion of fellows self-assessing at the highest competency level increased from 10% pre-programme to 39% post-programme, with corresponding increases in colleague feedback ratings from 17% to 49%. Qualitative data from open-ended survey responses and semi-structured interviews suggested improvements in leadership confidence, communication, and ability to influence AMS practice. Fellows reported leading prescribing improvements and multidisciplinary engagement, often without formal authority, with greater relative gains observed among Africa-based participants. Conclusions: UK-ALF-A was associated with enhanced leadership capability and contributions to AMS practice, alongside reported changes in individual and organisational practices that support broader health system strengthening, highlighting its value as a workforce development model.

3 September 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
AIAyesha Iqbal
Ayesha Iqbal
Yuhashinee KumaradevYuhashinee Kumaradev
Yuhashinee Kumaradev
GGGizem Gülpınar
Gizem Gülpınar
Claire Elizabeth BrandishClaire Elizabeth Brandish
Claire Elizabeth Brandish
Maxencia NabiryoMaxencia Nabiryo
Maxencia Nabiryo
VRVictoria Rutter
Victoria Rutter
Background: The hub-and-spoke model (HSM), offers a framework for efficient healthcare service delivery. This scoping review seeks to establish the implementation and effectiveness of the HSM in Antimicrobial Stewardship (AMS) programs. Methods: The Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR) reporting guideline was followed. A systematic search was conducted in four electronic databases (PubMed, Medline, Cochrane library and Google scholar) from inception until January 2024. Studies where the HSM was used for delivering any AMS activity, intervention or action, were included. No study specific filters were applied and all populations, study designs and health settings were included. Data screening and selection was achieved using Rayyan. Three authors independently screened studies, with conflicts resolved by a fourth author. Data were narratively synthesized. Standard appraisal tools were impractical; however, critically evaluation of data collection and outcome reporting was ensured. Results: Out of 1,438 articles, three were included in the scoping review. The primary interventions utilising the HSM in AMS involved reducing antibiotic misuse, training healthcare professionals, case-based learning, establishing AMS programs, developing antibiograms, and formulating policies or guidelines pertinent to AMS. The studies demonstrated significant clinical improvements in AMS. Clinical outcomes from the studies include a significant reduction in antimicrobial usage and improved antibiotic management, with a notable decrease in days on antimicrobial therapy and increased antibiotic de-escalation. Key facilitators for AMS program success: tailored education, collaborative learning, strong leadership, strategic practices, and data-driven decisions. Key barriers: leadership challenges, change resistance, knowledge gaps, inadequate data systems, resource limitations, and technological constraints. Conclusion: The review identified a literature gap in HSM use for AMS programs. Further studies are needed to assess HSM's effectiveness, feasibility, and cost-effectiveness in AMS contexts.